Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 16/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.58 |
| ▸ | PPARD | Q03181 | 2/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858638 | 1.00 | LMNA (0.62) | LMNAL3MBTL1FFAR1FFAR4PPARD | |
| SCHEMBL24723782 | 0.91 | LMNA (0.56) | LMNAL3MBTL1FFAR1FFAR4PPARD | |
| SCHEMBL24723565 | 0.85 | LMNA (0.64) | LMNAL3MBTL1FFAR1FFAR4PPARD | |
| SCHEMBL24723779 | 0.84 | LMNA (0.55) | LMNAL3MBTL1FFAR1FFAR4PPARD | |
| SCHEMBL7565298 | 0.83 | FFAR1 (0.61) | LMNAL3MBTL1FFAR1FFAR4PPARD | |
| SCHEMBL18265475 | 0.83 | PPARD (0.63) | LMNAL3MBTL1FFAR1FFAR4PPARD | |
| SCHEMBL3686436 | 0.82 | FFAR1 (0.59) | LMNAL3MBTL1FFAR1FFAR4PPARD | |
| SCHEMBL1205605 | 0.80 | LMNA (0.75) | LMNAL3MBTL1FFAR1FFAR4 | |
| SCHEMBL3097038 | 0.78 | PKM (0.53) | L3MBTL1 | |
| SCHEMBL4374887 | 0.78 | PKM (0.53) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835724-B2 | Topical antiinflammatory agents for treating inflammatory dermatoses | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-28 | — | — | US | disclosed |
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-01 | — | — | US | disclosed |
| CN-1056151-C | 17-deoxycorticosteroid-21-[O]-carboxylic esters, processes for their preparation and pharmaceuticals containing these compounds | HOECHST AG (DE) | 2000-09-06 | — | — | CN | disclosed |
| US-5824670-A | ANTIINFLAMMATORY AGENTS; TREATING DERMATOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-10-20 | — | — | US | disclosed |
| US-5608093-A | ANTIINFLAMMATORY AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-04 | — | — | US | disclosed |
| CN-1124250-A | 17-deoxycorticosteroid-21-[O]-carboxylic esters, processes for their preparation and pharmaceuticals containing these compounds | HOECHST AG (DE) | 1996-06-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103392-A1 | CORTICOID-17,21-DICARBOXYLIC ESTERS AND CORTICOSTEROID 17-CARBOXYLIC ESTER 21-CARBONIC ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | NR3C1, HSD3B1, HSD17B7 | LMNA 3177/4885L3MBTL1 3762/4885FFAR1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.